



**Contacts:**

Priti Radhakrishnan, I-MAK Director

917.703.2876

[priti.radhakrishnan@gmail.com](mailto:priti.radhakrishnan@gmail.com)

Alison Karam, APR, Public Relations

860-657-3815, x21, cell: (860) 906-6264

[karam@firstexperience.com](mailto:karam@firstexperience.com)

**Priti Radhakrishnan Awarded Pop!Tech 2008 Social Innovation Fellowship  
for I-MAK Work as World-Changing Innovator**

New York, NY, October 7, 2008 -- Priti Radhakrishnan, co-director of the non-profit Initiative for Medicines, Access and Knowledge (I-MAK), has been awarded a Pop!Tech 2008 Social Innovation Fellowship for her work as a world-changing innovator.

More than 100 submissions were received from 30 countries in Pop!Tech's search for the most outstanding visionary change agents to the world's social, economic and environmental challenges. Radhakrishnan was one of only 16 Social Innovation Fellows to be selected for the [2008 program](#).

Each Fellow is working on a transformative solution to a critical global challenge, in categories such as sustainable energy, human rights, education, economic development, healthcare and civic engagement. I-MAK's work in global healthcare defends public interest by ensuring that unmerited pharmaceutical monopolies and weak patent systems do not cause people to suffer and die preventable deaths, because they cannot afford the medicines that exist to help them.

The Pop!Tech program is designed to accelerate the positive impact of I-MAK's work by connecting Radhakrishnan with world-class thought leaders as well as the latest tools and thinking in emerging technology, design, communications, branding, funding and scalability. The program's faculty will lead the Fellows through an intensive four-day "boot camp" in Maine prior to the start of "Pop!Tech 2008: Scarcity and Abundance."

**About I-MAK**

The non-profit Initiative for Medicines, Access and Knowledge (I-MAK) is a team of lawyers and scientists working to strengthen patent systems and encourage innovation in new medicines, while expanding broad access to the best and latest treatments. The organization does this by reviewing pharmaceutical patents to strengthen patent examination, and selectively exposing unmerited pharmaceutical patents – which drive up the cost of essential drugs and prevent them from ever being accessible in less developed countries for poor patients. I-MAK's team is working to create technical analyses of 100 critical medicines and patents, which will help them preempt the granting of unmerited patents, increase accountability and ultimately make lifesaving drugs more affordable. I-MAK's patent information, databases, publications and presentations are available for reference at <http://www.i-mak.org/>.

---

I-MAK

New York, NY

917.703.2876

[priti.radhakrishnan@gmail.com](mailto:priti.radhakrishnan@gmail.com)

[www.i-mak.org](http://www.i-mak.org)